Novavax Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Novavax han disminuido a una tasa media anual de -30.4%, mientras que en la industria Biotechs los beneficios crecieron en un 12.8% anualmente. Los ingresos han ido creciendo a una tasa media de 46.5% al año.

Información clave

-23.9%

Tasa de crecimiento de los beneficios

-6.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	12.9%
Tasa de crecimiento de los ingresos	40.0%
Rentabilidad financiera	n/a
Margen neto	-40.0%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Novavax. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

BMV:NVAX * Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Mar 24	997	-399	427
31 Dec 23	984	-545	457
30 Sep 23	1,050	-549	464
30 Jun 23	1,597	-587	479
31 Mar 23	1,359	-1,155	505
31 Dec 22	1,982	-658	489
30 Sep 22	1,847	-1,322	411
30 Jun 22	1,291	-1,476	366
31 Mar 22	1,403	-1,318	331
31 Dec 21	1,146	-1,744	298
30 Sep 21	1,204	-1,075	273
30 Jun 21	1,182	-950	252
31 Mar 21	919	-615	196
31 Dec 20	476	-418	143
30 Sep 20	205	-273	92
30 Jun 20	50	-93	43
31 Mar 20	18	-115	35
31 Dec 19	19	-133	34
30 Sep 19	16	-150	35
30 Jun 19	21	-177	36
31 Mar 19	29	-182	34
31 Dec 18	34	-185	34
30 Sep 18	39	-186	34
30 Jun 18	39	-186	34
31 Mar 18	35	-186	34
31 Dec 17	31	-184	34
30 Sep 17	26	-190	34
30 Jun 17	21	-212	40
31 Mar 17	17	-247	45
31 Dec 16	15	-280	47
30 Sep 16	16	-302	47
30 Jun 16	19	-269	43
31 Mar 16	31	-210	36
31 Dec 15	36	-157	31
30 Sep 15	37	-110	27
30 Jun 15	39	-96	23
31 Mar 15	33	-94	21
31 Dec 14	31	-83	20
30 Sep 14	33	-65	18
30 Jun 14	29	-61	17
31 Mar 14	25	-56	15
31 Dec 13	21	-52	15
30 Sep 13	17	-46	13
30 Jun 13	18	-38	11

Ingresos de calidad: NVAX * actualmente no es rentable.

Margen de beneficios creciente: NVAX * actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: NVAX * no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 30.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de NVAX * en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: NVAX * no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-2.6%).

Rentabilidad financiera

Alta ROE: El pasivo de NVAX * supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Novavax Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings released: US$1.06 loss per share (vs US$3.41 loss in 1Q 2023)

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: US$5.41 loss per share (vs US$8.42 loss in FY 2022)

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Recent updates

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$1.06 loss per share (vs US$3.41 loss in 1Q 2023)

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax, Inc., Annual General Meeting, Jun 13, 2024

No longer forecast to breakeven

Full year 2023 earnings released: US$5.41 loss per share (vs US$8.42 loss in FY 2022)

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

New minor risk - Profitability

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.65 (vs US$6.53 loss in 2Q 2022)

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

New minor risk - Profitability

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: US$3.41 loss per share (vs US$2.66 profit in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$8.42 loss per share (vs US$23.44 loss in FY 2021)

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents

No longer forecast to breakeven

Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine

Third quarter 2022 earnings released: US$2.15 loss per share (vs US$4.31 loss in 3Q 2021)

Novavax, Inc. Revises Revenue Guidance for the Year 2022

Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc.'s COVID-19 Vaccine, Adjuvanted as a Booster for Adults

Novavax, Inc. Announces Positive Results from Phase 1/2 Clinical Trial of Its COVID-19-Influenza Combination (CIC) Vaccine Candidate

Novavax, Inc. Presents Data from the Phase 3 PREVENT-19 Trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax Covid-19 Vaccine as A Primary Series for Adults Aged 18 and Older

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as A Booster for Adults Aged 18 and Older

Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older

Novavax Nuvaxovid COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

Novavax, Inc. Nuvaxovid™ Covid-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

Novavax, Inc. announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as First and Second Booster for Adults

Novavax, Inc. Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

Forecast breakeven date pushed back to 2023

Novavax, Inc. Is Revises Revenue Guidance for Full Year 2022

Second quarter 2022 earnings released: US$6.53 loss per share (vs US$4.75 loss in 2Q 2021)

Novavax, Inc. Initiates Phase 2b/3 Hummingbird Global Clinical Trial for the Novavax Covid-19 Vaccine in Children Aged Six Months Through 11 Years

Desglose de ingresos y gastos
Beta